|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
LB-9
ARC-520 produces deep and durable knockdown of
viral antigens and DNA in a phase II study in patients
with chronic hepatitis B
Man-Fung Yuen1, Henry Lik-Yuen Chan2
, Sze Hang Kevin Liu1, Bruce Given3, Thomas Schluep3, James Hamilton3, Ching-Lung Lai1, Stephen Locarnini4, Johnson Y. Lau5, Carlo Ferrari6, Robert Gish7,8
; 1The University of Hong Kong, Hong Kong, China;
2The Chinese University of Hong Kong, Hong Kong, China;
3Arrowhead Research Corp., Pasadena, CA;
4Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC, Australia;
5Hong Kong Polytechnic University, Hong Kong, China;
6University of Parma, Parma, Italy;
7Stanford University, Palo Alto, CA;
8Hepatitis B Foundation, Doylestown, PA
Chronic hepatitis B (CHB) has become an important target for drug development. ARC-520 (ARC), the first RNA interference-based drug to reach patients (pts), targets ccc-DNA-derived mRNA; herein we report results in CHB.
Methods:
58 CHB pts (48 ARC, 10 placebo (PL), mean age 41 yrs (range 23-59) were included. 38 pts were HBeAg-neg and 20 HBeAg-pos. At entry, 32 of 38 HBeAg-neg and 14 of 20 HBeAg-
pos had taken entecavir (ETV) for mean of 5 yrs (range 2-8) and were on ETV throughout the study. 12 treatment naïve pts
(6 HBeAg-neg, 6 HBeAg-pos) started on ETV during the trial.
All pts received a single dose IV of ARC or PL (6 HBeAg-pos received a divided dose of ARC separated by 2 wks) and had viral parameter knockdown (KD) measured over 85 days [qHBsAg, HB core-related antigen (qHBcrAg) and viral DNA in all, qHBeAg in HBeAg-pos]. Doses were 1-4 mg/kg in HBeAg-neg. All HBeAg-pos received 4 mg/kg. 15 pts are continuing in follow-up.
Results:
ARC therapy was well tolerated - 23%
reported a mild or mod adverse event (AE) with no AE rated serious, severe, drug-related or causing withdrawal from the trial. Viral DNA was below level of quantitation in all chronic ETV pts at study entry. Naïve pts reduced viral DNA up to 4.3
log (mean 2.2 log) after ARC and ETV. ARC reduced viral antigens with qHBeAg best KD of 1.7 log (mean max 1.2 log)
following a single 4 mg/kg dose. In naïve pts, best qHBsAg KD of 1.9 log (mean max 1.1 log) in HBeAg-pos and 0.7 log
(mean max 0.2 log) in HBeAg-neg were observed. qHBcrAg showed a dose response in HBeAg-neg with best KD at 1 mg/kg of 0.18 log (mean max 0.15 log) and 1.1 log (mean max 0.9 log) with 4 mg/kg. HBeAg-pos showed best KD of 1.1 log
(mean max 0.92 log). The qHBsAg dose response was less deep in chronic ETV pts with best observed reduction of 0.3
log (mean max 0.2 log) observed at 1 mg/kg vs 0.5 log (mean max 0.4 log) at 4 mg/kg in HBeAg-neg. Best qHBsAg KD in
chronic ETV treated HBeAg-pos was 0.7 log (mean max 0.3 log). Divided doses at 4 mg/kg did not increase antigen KD.
Duration of qHBsAg KD was typically 8 wks with 2 distinct KD patterns of qHBsAg seen: an immediate, direct ARC antiviral effect (~70% of pts) and a delayed response several weeks after treatment (~30% of pts).
Conclusions:
1) These findings are consistent with more cccDNA-driven antigen production
in HBeAg-pos. 2) ARC was well tolerated 3) ARC effectively inhibited cccDNA-derived mRNA with protein KD up to 1.9
logs (99%) observed 4) These variations in viral protein KD are consistent with ARC data in chimps and previously reported
chronic ETV reductions in pts for cccDNA 5) Chronic ARC studies aimed at producing HBsAg seroclearance are underway.
Man-Fung Yuen - Advisory Committees or Review Panels: GlaxoSmithKline,
Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, Pfizer,
GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, Pfizer; Grant/Research Support: Roche, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Science, Roche, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Science, Roche, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Science, Roche, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Science
Henry Lik-Yuen Chan - Advisory Committees or Review Panels: Gilead, MSD, Bristol-Myers Squibb, Roche, Novartis Pharmaceutical, Abbvie; Speaking and Teaching: Echosens
Bruce Given - Employment: Arrowhead Research Corp; Stock Shareholder: Icon plc
Thomas Schluep - Employment: Arrowhead Research Corp.
James Hamilton - Employment: Arrowhead Research Corp
Ching-Lung Lai - Advisory Committees or Review Panels: Bristol-Myers Squibb, Gilead Sciences Inc; Consulting: Bristol-Myers Squibb, Gilead Sciences, Inc;
Speaking and Teaching: Bristol-Myers Squibb, Gilead Sciences, Inc
Stephen Locarnini - Consulting: Gilead, Arrowhead; Employment: Melbourne Health
Johnson Y. Lau - Advisory Committees or Review Panels: Arrowhead Research;
Management Position: Kinex Pharmaceuticals, Avalon BioMedical Management; Speaking and Teaching: Hong Kong Polytechnic University, University of Hong Kong, Southwestern Hospital
Carlo Ferrari - Advisory Committees or Review Panels: Gilead, Roche, Abbvie, BMS, Merck, Arrowhead; Grant/Research Support: Gilead, Roche, Janssen
Robert Gish - Advisory Committees or Review Panels: Gilead, AbbVie, Arrowhead; Consulting: Eiger, Isis, Genentech; Speaking and Teaching: Gilead, AbbVie; Stock Shareholder: Arrowhead
The following people have nothing to disclose: Sze Hang Kevin Liu
|
|
发表于 2015-10-21 16:58
